-- 奥罗宾多制药（Aurobindo Pharma，NSE：AUROPHARMA，BOM：524804）位于印度特伦甘纳邦马哈布布纳加尔地区的口服固体制剂生产厂接受美国食品药品监督管理局（FDA）检查后，FDA发出了一份“建议采取自愿行动”的通知。 根据周三提交给印度证券交易所的文件，此次检查于1月28日至2月10日进行，FDA出具了一份包含九项观察结果的“483表格”。 此次检查已结束。 该公司股价在近期交易中上涨超过3%。
Related Articles
Mining & Metals
Earnings Flash (SDE.TO) Spartan Delta Corp. Increased 2026 Guidance and Increase To Credit Facility
$SDE.TO
Asia
ValueMax Raises SG$24 Million Through Digital Securities Issuance
ValueMax (SGX:T6I) raised over SG$23.9 million through the issuance of digital securities on the SDXX platform, according to a Wednesday filing with the Singapore Exchange.The issuance will be listed on the SDXX platform on May 7, the filing added.
$SGX:T6I
Mining & Metals
Earnings Flash (ADEN.TO) ADENTRA Posted Q1 Adjusted EPS US$0.38 per Share, vs. FactSet Est of $0.31
$ADEN.TO